(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/254227 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/GB2022/051413

(22) International Filing Date:
06 June 2022 (06.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2107994.2 04 June 2021 (04.06.2021) GB

(71) Applicant: **KYMAB LIMITED** [GB/GB]; The Bennet Building (B930), Babraham Research Campus, Cambridge CB22 3AT (GB).

(72) Inventors: **NEWTON, Anthea**; c/o Kymab Limited, The Bennet Building (B930), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **PALU, Cintia Cristina**; c/o Kymab Limited, The Bennet Building (B930), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **QUARATINO, Sonia**; c/o Kymab Limited, The Bennet Building (B930), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **SAINSON, Richard Charles Alfred**; c/o Kymab Limited, The Bennet Building (B930), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **DEANTONIO, Cecilia**; c/o Kymab Limited, The Bennet Building (B930), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). **WAKE, Matthew Stephen**; c/o Kymab Limited, The Bennet Building (B930), Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).

(74) Agent: **HEATH, Abigail**; KIlburn & Strode LLP, Lacon London, 84 Theobalds Road, LONDON Greater London WC1X 8NL (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2022/254227 A1

(54) Title: TREATMENT OF PD-L1 NEGATIVE OR LOW EXPRESSING CANCER WITH ANTI-ICOS ANTIBODIES

(57) Abstract: This invention relates to compositions and methods for the treatment of cancer, in particular difficult-to-treat cancers. More specifically, the present invention relates to compositions and methods for the treatment of PD-L1 negative or PD-L1 low expressing cancers using a modulator of ICOS, such as an anti-ICOS antibody, either alone or in combination with other agents, such as an anti-PD-L1 antibody.